Clinical Trial Update: A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection [Phase 2]

View source ↗

Summary

A multicenter Phase 2 clinical trial evaluating adjuvant icotinib in EGFR-mutant stage I non-small cell lung cancer at high risk of recurrence after complete re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Wu Nan | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN